Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 150
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 151
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
LATEST NEWS UPDATES | Vaccine against dengue to be tested in India -Kounteya Sinha

Vaccine against dengue to be tested in India -Kounteya Sinha

Share this article Share this article
published Published on Nov 19, 2012   modified Modified on Nov 19, 2012
-The Times of India

PARIS: The world's most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015.

The vaccine will be tested on 120-odd adults in the beginning, the results of which should be available by 2013. Thereafter, a largescale study on children — the main target group — will be undertaken.

In an exclusive interview, French pharma giant Sanofi Pasteur's CEO Christopher Viehbacher told TOI, "Sites for the vaccine's final trials will stretch from Thailand to India as this vaccine has to work on populations across countries. We will test it in India soon."

Dr Jean Lang, head of the vaccine's R&D programme, added, "The drug controller general of India has asked us to conduct phase II safety trials on adults first, then on children. It will help us get licence to market the vaccine in India faster if it has been tested on the Indian population and is found safe and effective."

Vaccine fights 3 of 4 dengue strains

Even the world's most effective dengue vaccine candidate, set for trials in India soon, will not be able to counter all virus strains, early tests have showed.

There is currently no vaccine to protect against dengue, and efforts to develop one have been hamstrung since four viruses (known as DENV 1, 2, 3 and 4) cause the disease. Researchers in France and Thailand recently announced that the vaccine under trials — French pharma giant Sanofi Pasteur's CYD-TDV — was tested for its effectiveness on a group of 4,002 schoolchildren in Thailand, aged four to eleven. Secondary tests showed that the vaccine was effective against DENV 1, 3 and 4 but not on DENV 2, which appeared to be resistant. The vaccine showed a 60-90% protection rate against three main virus strains (DENV 1, 3 and 4).

"We are trying to find out why the vaccine wasn't very effective against the strain type 2," said Sanofi's global R&D president Dr Elias Zerhouni. "We are also working on designing a separate vaccine to combat type 2 and a separate vaccine effective against the other three strains of dengue."

Sources told TOI that a high-level meeting was held between scientists from Sanofi's dengue vaccine team and Indian experts, including former director general of the Indian Council of Medical Research Dr N K Ganguly, in New Delhi to discuss the India trials which will begins soon.

Dr A C Dhariwal, head of India's National Vector Borne Disease Control Programme, said, "It is the strain 2 that causes dengue hemorrhagic fever which is life-threatening. And this vaccine does not protect against this strain." Of the estimated 230 million people infected annually, two million — mostly children — develop dengue hemorrhagic fever (DHF), a severe form of the disease. According to Jean Lang, head of the vaccine's R&D programme, largescale phase III clinical studies of the vaccine are presently under way on 31,000 adults and children in 10 countries — Mexico, Colombia, Honduras, Puerto Rico, Brazil, the Philippines, Vietnam, Malaysia, Indonesia and Thailand. 

The Times of India, 19 November, 2012, http://timesofindia.indiatimes.com/home/science/Vaccine-against-dengue-to-be-tested-in-India/articleshow/17274153.cms


Related Articles

 

Write Comments

Your email address will not be published. Required fields are marked *

*

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close